It is reasonable to assume, therefore, that in RCCs – and probably also in AML – increased expression of antiapoptotic XIAP contributes to reduced apoptosis susceptibility of tumour cells, thereby providing an important survival advantage during tumour progression. The gene discussed is XIAP; the disease is neoplasm.